MCID: MCN001
MIFTS: 51

Mucinous Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Mucinous Adenocarcinoma

MalaCards integrated aliases for Mucinous Adenocarcinoma:

Name: Mucinous Adenocarcinoma 12 15 73
Mucin-Producing Adenocarcinoma 12 73
Pseudomyxoma Peritonei with Unknown Primary Site 12
Mucin-Secreting Adenocarcinoma 12
Mucin-Secreting Carcinoma 12
Adenocarcinoma, Mucinous 44
Mucous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3030
MeSH 44 D002288
SNOMED-CT 68 72495009 900006

Summaries for Mucinous Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which produce mucin.

MalaCards based summary : Mucinous Adenocarcinoma, also known as mucin-producing adenocarcinoma, is related to endometrial mucinous adenocarcinoma and ovarian mucinous adenocarcinoma. An important gene associated with Mucinous Adenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Pathways in cancer and Development EGFR signaling pathway. The drugs Fluorouracil and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include colon, prostate and appendix, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Mucinous Adenocarcinoma

Diseases related to Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 332)
# Related Disease Score Top Affiliating Genes
1 endometrial mucinous adenocarcinoma 33.8 CDKN2A MUC1
2 ovarian mucinous adenocarcinoma 33.5 CDX2 KRT20 KRT7 MUC2
3 appendix adenocarcinoma 33.3 CDX2 KRT20 KRT7
4 pseudomyxoma peritonei 32.0 CDX2 KRAS KRT20 KRT7 MUC1 MUC2
5 mucinous lung adenocarcinoma 31.6 ALK EGFR KRAS NRG1
6 mucinous bronchioloalveolar adenocarcinoma 31.1 CDKN2A CDX2 KRT20 KRT7 MUC1 NKX2-1
7 adenocarcinoma 30.9 ALK CDKN2A EGFR KRAS MLH1 MUC1
8 teratoma 30.7 CDX2 KRT7 NKX2-1
9 colon adenocarcinoma 30.4 KRAS KRT20 MLH1
10 thymus adenocarcinoma 30.3 CDX2 KRT20 KRT7
11 sertoli-leydig cell tumor 30.3 KRT7 MUC1
12 cystadenocarcinoma 30.3 KRT7 MUC1 MUC2
13 ovarian germ cell teratoma 30.2 KRT7 NKX2-1
14 cystic teratoma 30.1 CDX2 KRT20 KRT7 MUC2 NKX2-1
15 villous adenoma 30.1 CDX2 KRAS KRT20 MUC1
16 vulva adenocarcinoma 30.1 CDKN2A CDX2 KRT20 KRT7
17 rectum adenocarcinoma 30.0 CDX2 KRT20 KRT7
18 small intestine adenocarcinoma 30.0 MLH1 MUC2
19 eyelid carcinoma 29.9 KRT20 KRT7 MUC2
20 dermoid cyst 29.8 KRT20 KRT7 MUC1
21 carcinosarcoma 29.8 KRAS KRT7 MUC1
22 adenocarcinoma in situ 29.8 CDKN2A CDX2 KRAS KRT20 KRT7
23 intestinal obstruction 29.8 CDX2 KRT20 KRT7
24 microinvasive gastric cancer 29.7 CDX2 MLH1 MUC2
25 cystadenoma 29.7 KRT20 KRT7 MUC1 MUC2
26 transverse colon cancer 29.7 KRT20 KRT7
27 thymus cancer 29.7 KRT7 MUC1 NKX2-1
28 large cell neuroendocrine carcinoma 29.7 EGFR KRT20 KRT7 NKX2-1
29 adenoid cystic carcinoma 29.7 KRAS KRT20 KRT7 MUC1
30 endocervical adenocarcinoma 29.6 CDKN2A CDX2 KRT20 KRT7
31 gastrointestinal stromal tumor 29.5 CDKN2A EGFR KRAS
32 appendix cancer 29.5 CDX2 KRT20 KRT7 MUC1 MUC2
33 peritoneal mesothelioma 29.5 CDKN2A EGFR MUC1
34 mucoepidermoid carcinoma 29.4 EGFR KRT7 MUC1 MUC2
35 renal cell carcinoma, nonpapillary 29.3 EGFR KRT20 KRT7 MUC1 NKX2-1
36 transitional cell carcinoma 29.2 CDKN2A EGFR KRT20 KRT7
37 endometrial cancer 29.2 CDKN2A EGFR KRAS KRT7 MLH1
38 adenosquamous carcinoma 29.2 EGFR KRAS KRT7 MUC1 NKX2-1
39 horseshoe kidney 29.1 CDX2 EGFR KRT20 KRT7 NKX2-1
40 gastric cancer 29.0 CDKN2A CDX2 EGFR KRAS KRT20 MLH1
41 ovarian cancer 29.0 EGFR KRAS KRT7 MLH1 MUC1 MUC2
42 pancreas adenocarcinoma 29.0 CDKN2A CDX2 EGFR KRAS MUC1 MUC2
43 gallbladder cancer 28.9 CDKN2A EGFR KRAS MLH1 MUC1 MUC2
44 colorectal adenocarcinoma 28.8 CDX2 EGFR KRAS KRT20 KRT7 MLH1
45 colorectal cancer 28.8 CDKN2A CDX2 EGFR KRAS KRT20 KRT7
46 gastric adenocarcinoma 28.7 CDKN2A CDX2 EGFR KRAS KRT20 KRT7
47 lung cancer susceptibility 3 28.2 ALK CDKN2A CDX2 EGFR KRAS KRT20
48 lung cancer 28.0 ALK CDKN2A EGFR KRAS KRT20 KRT7
49 signet ring cell variant cervical mucinous adenocarcinoma 12.4
50 villoglandular variant cervical mucinous adenocarcinoma 12.4

Graphical network of the top 20 diseases related to Mucinous Adenocarcinoma:



Diseases related to Mucinous Adenocarcinoma

Symptoms & Phenotypes for Mucinous Adenocarcinoma

GenomeRNAi Phenotypes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.81 EGFR KRAS MUC1
2 Decreased viability GR00106-A-0 9.81 KRAS
3 Decreased viability GR00221-A-1 9.81 ALK CDKN2A EGFR KRAS
4 Decreased viability GR00221-A-2 9.81 KRAS
5 Decreased viability GR00221-A-3 9.81 CDKN2A
6 Decreased viability GR00221-A-4 9.81 ALK CDKN2A EGFR
7 Decreased viability GR00301-A 9.81 KRAS
8 Decreased viability GR00381-A-1 9.81 KRAS
9 Decreased viability GR00402-S-2 9.81 ALK CDKN2A EGFR KRAS MUC1
10 Decreased cell migration GR00055-A-1 9.26 ALK EGFR KRAS MUC1

MGI Mouse Phenotypes related to Mucinous Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.03 CDKN2A CDX2 EGFR KRAS KRT7 MLH1
2 endocrine/exocrine gland MP:0005379 9.97 ALK CDKN2A CDX2 EGFR KRAS MLH1
3 homeostasis/metabolism MP:0005376 9.97 ALK CDKN2A CDX2 EGFR KRAS KRT7
4 digestive/alimentary MP:0005381 9.95 CDKN2A CDX2 EGFR KRAS MLH1 MUC2
5 neoplasm MP:0002006 9.86 ALK CDKN2A CDX2 EGFR KRAS MLH1
6 reproductive system MP:0005389 9.5 ALK CDKN2A CDX2 EGFR KRAS MLH1
7 pigmentation MP:0001186 9.46 ALK CDKN2A EGFR KRAS
8 respiratory system MP:0005388 9.1 ALK CDKN2A EGFR KRAS MLH1 NKX2-1

Drugs & Therapeutics for Mucinous Adenocarcinoma

Drugs for Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
2
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
3
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
4
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
5
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
6
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
7
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
8
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
9
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
10
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
11
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
12
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
13
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
14
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
15
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123948-87-8, 119413-54-6 60700
16
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
17
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
18
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
19
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
20
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
21
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
22
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
23
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
24
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 14219 4091
25
Letrozole Approved, Investigational Phase 2, Phase 3,Phase 3 112809-51-5 3902
26
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
27
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
28
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
30
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
31
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
32
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
33
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
34
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
35
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
36 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
37 Nucleic Acid Synthesis Inhibitors Phase 3
38 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
40 Alkylating Agents Phase 3,Phase 2,Phase 1
41 Calcium, Dietary Phase 3,Phase 2,Phase 1
42 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Vitamins Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
45 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
46 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Mitomycins Phase 3
48 Folate Phase 3,Phase 2,Phase 1,Not Applicable
49 Antidotes Phase 3,Phase 2,Phase 1
50 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 207)
# Name Status NCT ID Phase Drugs
1 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
2 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
3 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
4 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
5 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
8 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
9 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
10 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
11 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
12 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
13 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
14 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
15 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
16 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
17 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
18 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
19 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
20 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
21 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
22 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
23 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
24 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
25 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
26 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
27 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
28 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
29 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
30 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
31 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
32 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
33 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
34 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
35 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
36 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
37 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
38 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
39 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
40 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
41 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
42 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
43 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
44 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
45 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
46 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
47 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
48 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
49 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
50 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride

Search NIH Clinical Center for Mucinous Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, mucinous

Genetic Tests for Mucinous Adenocarcinoma

Anatomical Context for Mucinous Adenocarcinoma

MalaCards organs/tissues related to Mucinous Adenocarcinoma:

41
Colon, Prostate, Appendix, Lung, Ovary, Pancreas, Cervix

Publications for Mucinous Adenocarcinoma

Articles related to Mucinous Adenocarcinoma:

(show top 50) (show all 656)
# Title Authors Year
1
Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung. ( 29371584 )
2018
2
Mucinous Adenocarcinoma of the Scalp: Primary Cutaneous Neoplasm Versus Underlying Metastatic Disease. ( 29876191 )
2018
3
Right-colon mucinous adenocarcinoma mimicking a hydatid cyst. ( 29313694 )
2018
4
GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4I+ expression, and KRAS mutations. ( 29469192 )
2018
5
Multicystic mucinous adenocarcinoma of the uterine cervix compared with benign multicystic lesions: Multiparametric MR features. ( 29624774 )
2018
6
Case of mucinous adenocarcinoma of the lung associated with congenital pulmonary airway malformation in a neonate. ( 29441110 )
2018
7
Primary Mucinous Adenocarcinoma of Skin: Myoepithelial Cells are a Clue to its Diagnosis. ( 29692460 )
2018
8
Duodenal mucinous adenocarcinoma presenting as ileus, obstructive jaundice and massive ascites: A case report. ( 29456851 )
2018
9
Mucinous adenocarcinoma arising from chronic perianal fistula mimicking horseshoe abscess. ( 29622704 )
2018
10
Laparoscopic abdominoperineal resection for the treatment of a mucinous adenocarcinoma associated with an anal fistula. ( 29593864 )
2018
11
Acinar-Predominant Pattern Correlates With Poorer Prognosis in Invasive Mucinous Adenocarcinoma of the Lung. ( 29538611 )
2018
12
Pseudomyxoma Peritonei Arising From Urachal Mucinous Adenocarcinoma. ( 29024737 )
2018
13
Frequent <i>NRG1</i> fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. ( 29515761 )
2018
14
Perianal Mucinous Adenocarcinoma Diagnosed by Histological Study of Anorectal Abscess with Fistula. ( 29577055 )
2018
15
Perianal Paget disease secondary to pagetoid spread of mucinous adenocarcinoma of the anal canal. ( 29400297 )
2018
16
Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma. ( 29375717 )
2018
17
hCG production by mucinous adenocarcinoma of the ovary in a reproductive aged woman. ( 30533474 )
2018
18
A rare case of incidental mucinous adenocarcinoma with osseous metaplasia associated with cysts of the presacral space. ( 30460902 )
2018
19
Mucinous adenocarcinoma of gallbladder: Subcategorisation on fine-needle aspiration cytology. ( 30375181 )
2018
20
Anaplastic Carcinoma Arising From Ovarian Mucinous Adenocarcinoma With Massive Cardiopulmonary Metastasis: An Autopsy Case Report. ( 30393058 )
2018
21
Trends of incidence and survival in patients with gastrointestinal mucinous adenocarcinoma. ( 30344730 )
2018
22
Multicentric Mucinous Adenocarcinoma in the Periorbital Region. ( 30365480 )
2018
23
Intestinal epithelial Notch-1 protects from colorectal mucinous adenocarcinoma. ( 30323897 )
2018
24
Primary mucinous adenocarcinoma of the eyelid: A case report and literature review. ( 30251739 )
2018
25
Invasive mucinous adenocarcinoma of the lung in a 19-year-old female. ( 30269525 )
2018
26
Incidental discovery of mucinous adenocarcinoma of the prostate following transurethral resection of the prostate: A report of two cases and a literature review. ( 30214732 )
2018
27
Colonic adenosquamous carcinoma and mucinous adenocarcinoma with microsatellite instability. ( 30173239 )
2018
28
Urachal mucinous adenocarcinoma in the pelvic wall mimicking endometriosis. ( 30108674 )
2018
29
Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. ( 29992451 )
2018
30
Can Quantitative Volumetric Analysis Predict Tumor Recurrence in the Patients with Mucinous Adenocarcinoma of the Lung After Surgical Resection? ( 30064921 )
2018
31
Effect of invasive mucinous adenocarcinoma on lung cancer-specific survival after surgical resection: a population-based study. ( 30069357 )
2018
32
Favorable response to pemetrexed, cisplatin and bevacizumab in invasive mucinous adenocarcinoma: A case report and literature review. ( 30101020 )
2018
33
Mucinous adenocarcinoma of the thymus: report of a case. ( 28474330 )
2018
34
Endocrine Mucin-Producing Sweat Gland Carcinoma of the Eyelid Associated With Mucinous Adenocarcinoma. ( 28902090 )
2018
35
Rare Case of Iliopsoas Abscess Secondary to Mucinous Adenocarcinoma of the Colon: A Case Report. ( 29854689 )
2018
36
Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma. ( 29983574 )
2018
37
Mucinous adenocarcinoma and non-mucinous adenocarcinoma: differing clinicopathological characteristics and computed tomography features in gastric cancer. ( 28501848 )
2017
38
Characteristics and prognostic factors of colorectal mucinous adenocarcinoma with signet ring cells. ( 29138597 )
2017
39
Mucinous adenocarcinoma with lepidic pattern and with K-RAS mutation in a newborn with antenatal diagnosis of congenital pulmonary airway malformation. ( 28889407 )
2017
40
Mucinous adenocarcinoma arising in an end ileostomy - a video vignette. ( 28677338 )
2017
41
Primary Mucinous Adenocarcinoma of the Thymus: A Case Report and Literature Review. ( 28956749 )
2017
42
Comment on: External Validation of the Simplified Preoperative Assessment for Low-Grade Mucinous Adenocarcinoma of the Appendix. ( 29124485 )
2017
43
Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. ( 28590015 )
2017
44
Primary mucinous adenocarcinoma of the vulva, intestinal type. ( 28791269 )
2017
45
Fluorodeoxyglucose-avid pulmonary mucinous adenocarcinoma presenting with nonfluorodeoxyglucose-avid cystic brain lesions of unknown etiopathology: Brain magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography-computed tomography imaging features and additional value of whole-body positron emission tomography acquisition. ( 29199669 )
2017
46
Cystic metastasis from a mucinous adenocarcinoma of duodenum mimicking type II choledochal cyst: A case report. ( 29290919 )
2017
47
The Importance of Appendectomy in Surgery for Mucinous Adenocarcinoma of the Ovary. ( 28060142 )
2017
48
Mixed mucinous adenocarcinoma and somatostatinoma of the ampulla of Vater associated with neurofibromatosis type 1. ( 28693748 )
2017
49
Mucinous adenocarcinoma of unknown primary presenting with dysphagia. ( 29223385 )
2017
50
Mucinous adenocarcinoma in association with hidradenitis suppurativa. ( 28597923 )
2017

Variations for Mucinous Adenocarcinoma

Expression for Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Mucinous Adenocarcinoma.

Pathways for Mucinous Adenocarcinoma

Pathways related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1 12.38 ALK CDKN2A EGFR KRAS MLH1
2
Show member pathways
12.15 EGFR KRAS MUC1 NRG1
3
Show member pathways
12.09 ALK EGFR KRAS NRG1
4
Show member pathways
12.02 ALK CDKN2A EGFR KRAS NRG1
5 11.9 EGFR KRAS MLH1
6 11.82 ALK EGFR NRG1
7
Show member pathways
11.77 CDKN2A CDX2 EGFR KRAS MLH1 MUC2
8
Show member pathways
11.75 EGFR KRAS NRG1
9 11.65 CDKN2A EGFR KRAS
10
Show member pathways
11.61 EGFR KRAS NRG1
11 11.36 CDKN2A EGFR KRAS
12 11.09 EGFR KRAS NRG1
13 10.97 EGFR KRAS
14
Show member pathways
10.94 EGFR KRAS

GO Terms for Mucinous Adenocarcinoma

Biological processes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.62 CDKN2A KRAS NKX2-1 NRG1
2 positive regulation of protein phosphorylation GO:0001934 9.58 ALK EGFR KRAS
3 peptidyl-tyrosine phosphorylation GO:0018108 9.54 ALK EGFR NRG1
4 epithelial tube branching involved in lung morphogenesis GO:0060441 9.26 KRAS NKX2-1
5 positive regulation of cellular senescence GO:2000774 9.16 CDKN2A KRAS
6 cerebral cortex cell migration GO:0021795 8.96 EGFR NKX2-1
7 stimulatory C-type lectin receptor signaling pathway GO:0002223 8.8 KRAS MUC1 MUC2

Molecular functions related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 8.8 ALK EGFR NRG1

Sources for Mucinous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....